Agenus Inc. (NASDAQ: AGEN) reported its fourth‑quarter and full‑year 2025 financial results on March 16 2026. The company posted a net loss of $10.6 million for the quarter, a sharp improvement from the $46.8 million loss recorded in Q4 2024. For the full year, the loss narrowed to $3.1 million, compared with a $232.3 million loss in 2024, reflecting a significant reduction in operating expenses and the impact of the recently closed Zydus Lifesciences collaboration.
Operating cash burn for Q4 2025 rose to $25.6 million from $18.4 million in Q3 2025, driven by higher research and development outlays and a one‑time restructuring charge. The company’s cash on hand at the end of 2026 is projected to be approximately $3.5 million, underscoring ongoing liquidity challenges despite the capital infusion from the Zydus deal.
The Zydus Lifesciences collaboration, which closed on January 15 2026, provides an upfront payment of $75 million, a $16 million equity investment, and up to $50 million in milestone payments, bringing the total value to $141 million. The transaction secures dedicated U.S. manufacturing capacity for Agenus’ botensilimab/balstilimab (BOT/BAL) program and grants Zydus exclusive rights to develop and commercialize BOT and BAL in India and Sri Lanka.
Management emphasized that the collaboration strengthens the balance sheet and supports disciplined execution in 2026. "Closing this collaboration with Zydus strengthens our balance sheet and, critically, secures dedicated U.S. manufacturing capacity at a pivotal moment for Agenus," said Chairman and CEO Garo Armen. He added that the company will focus on advancing the Phase 3 program, broadening paid patient access, and progressing toward regulatory submission.
Agenus generated approximately $4.2 million in net revenue from early‑access programs in 2025, while the company ended Q1 2025 with $18.5 million in cash and cash equivalents, down from $40.4 million at the end of 2024. Management has expressed substantial doubt about the company’s ability to continue as a going concern for one year after filing, highlighting the need for continued capital raising and cost discipline.
The BOT/BAL program remains the company’s most promising clinical asset, with recent data showing a two‑year overall survival of 42% in refractory MSS colorectal cancer patients. The global Phase 3 BATTMAN trial is underway, and the company is pursuing additional indications and market access pathways.
Overall, the earnings release signals a significant narrowing of losses and a strategic focus on the BOT/BAL program, but liquidity constraints and high operating costs continue to pose risks to the company’s near‑term financial stability.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.